The mechanistic target of rapamycin (mTOR) pathway diseases (Table 1) is a group of rare early-onset, hard-to-treat genetic diseases with symptoms ranging from benign tumours in multiple organs to brain malformations causing epilepsy, each of which is managed in disconnected medical disciplines (Fig. 1). This evidence concerns the gene MTOR and benign neoplasm.